Meme Kanseri Proteom Profilinin Yüzey Geliştirilmiş Lazer Desorpsiyon / İyonizasyon Uçuş Kütle Spektrometrisi (SELDI-TOF MS) ile Belirlenmesi

AMAÇ: Yüzey geliştirilmiş lazer desorpsiyon / iyonizasyon (SELDI) Uçuş kütle spektrometrisi (TOF MS) kullanılarak erken evre meme kanseri hastalarında serum proteom profilinde protein markerlar tanımlandı.YÖNTEMLER: Serum proteom fraksiyonlarını ayrımlama için metal iyon kromatografi (IMAC30-Cu) kullanıldı ve farklı şekilde eksprese olan peptitler (m / z; p

Anahtar Kelimeler:

Serum proteomik profil, SELDI-TOF MS, meme kanseri

Objective: Surface-enhanced laser desorption/ionization time-of flight mass spectrometry (SELDI-TOF MS) was used to screen serum proteomic profiling to identify protein markers for early breast cancer patients. Methods: We used metal ion affinity chromatography (IMAC30-Cu) for serum proteome fractionation technique and identify differentially expressed peptides (m/z; P < 0.0001) from benign disease and healthy controls as potential biomarkers of early breast cancer. The mass spectra, analyzed using ProteinChip Data Manager Software, distinguished between patients and healthy individuals based on k-nearest neighbor genetic algorithm. We collected 70 serum samples from patients with breast cancer (62 invasive breast carcinoma; 8 ductal carcinoma in situ), 31 bening disease and 37 healthy individuals. Results: Forty two peaks showed statistically significantly different intensities between cases and controls (P<0.05); 10 protein peaks were differentially expressed between the patients and benign disease. These results indicate that there are differences in serum protein expression among the three different groups of patients. Conclusion: SELDI-TOF MS could be used to screen blood samples for the early detection of breast cancer patients. Serum proteomic profiling by SELDI-TOF MS is a novel potential tool for the clinical diagnosis of patients with breast carcinoma.

Keywords:

serum proteomic profiling, SELDI-TOF MS, Breast carcinoma,

PDF

___

Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007; 57 (1): 43-669.
Petterson SD, Aebersold RH. Proteomics: First decade and beyond. Nature Genetics Supplement 2003; 33: 311-32.
Baskın Y. Tıpta teknolojik gelişimin neden olduğu kavram değişimleri: kişiselleştirilmiş tıp. Türk Hijyen ve Deneysel Tıp Dergisi, 2007; 64(2): 54-59. 4. Baskın Y. Yigitbası T. Clinical Proteomics of Breast Cancer. Current Genomics, 2010; 11 (7): 528-536.
Celis JE, Gromov P. Proteomics in tranlational cancer research: Toward an integrated approach. Cancer Cell 2003; 3: 9-15.
Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002; 48: 1296–1304.
Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature, 2008; 452:571– 579.
Becker S, Cazares LH, Watson P et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol, 2004; 11: 907– 914.
Laronga C, Becker S, Watson P et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers, 2003; 19: 229–238
Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer. Mol. Cel. Proteomics, 2006; 5 (10): 1772-1786.
Belluco C, Petricoin EF, Mammano E et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol, 2007; 14: 2470–2476.
Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem, 2002; 48: 1296–1304.
Li J, Orlandi R, White CN et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (Kyoto), 2005; 51: 2229– 2235.
Mathelin C, Cromer A, Wendling C et al. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat, 2006; 96: 83–90.
Van Winden AWJ, Gast MCW, Beijnen JH et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics, 2009; 19: 2-4.
Goncalves A, Esterni B, Bertucci F et al. Postoperative serum proteomic profiles may predict metastatic relapse in highrisk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene, 2006; 25: 981–989.
Song J, Patel M, Rosenzweig CN et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ ionization- based immunoassay. Clin Chem, 2006; 52: 1045–1053.
Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease peptidome patterns. J Clin Invest, 2006; 116:271–284.
Fung ET, Yip TT, Lomas L et al. Classification of cancer tumor-specific serum types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer, 2005; 115:783-789.
Goldsmith GH Hemostatic changes in patients with malignancy. Int J Hematol, 2001; 73: 151–156.
Shi Q, Harris LN, Lu X et al. Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res, 2006; 5: 2947–2955.
Atahan K, Küpeli H, Gür S ve ark.The value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer. International Journal of Medical Sciences, 2011; 8(2): 148-155. http://edergi.cbu.edu.tr/ojs/index.php/cbusbed isimli
SBED başlıklı eseri bu Creative Commons Alıntı-Gayriticari 4.0
Uluslararası Lisansı ile lisanslanmıştır. yazarın CBU